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Similarities between acylcarnitine 
profiles in large for gestational age 
newborns and obesity
Paula Sánchez-Pintos1, Maria-Jose de Castro1, Iria Roca1, Segundo Rite2, Miguel López3,4 & 
Maria-Luz Couce1
Large for gestational age (LGA) newborns have an increased risk of obesity, insulin resistance, and 
metabolic syndrome. Acylcarnitine profiles in obese children and adults are characterized by increased 
levels of C3, C5, and certain medium-chain (C12) and long-chain (C14:1 and C16) acylcarnitines. C2 is 
also increased in insulin-resistant states. In this 1-year observational study of 2514 newborns (246 LGA 
newborns, 250 small for gestational age (GA) newborns, and 2018 appropriate for GA newborns), we 
analyzed and compared postnatal acylcarnitine profiles in LGA newborns with profiles described for 
obese individuals. Acylcarnitine analysis was performed by tandem mass spectrometry on dried-blood 
spots collected on day 3 of life. LGA newborns had higher levels of total short-chain acylcarnitines 
(p < 0.001), C2 (p < 0.01) and C3 (p < 0.001) acylcarnitines, and all C12, C14, and C16 acylcarnitines 
except C12:1. They also had a higher tendency towards carnitine insufficiency (p < 0.05) and carnitine 
deficiency (p < 0.001). No significant differences were observed between LGA newborns born to 
mothers with or without a history of gestational diabetes. This novel study describes a postnatal 
acylcarnitine profile in LGA with higher levels of C2, C3, total acylcarnitines, and total short-chain 
acylcarnitines that is characteristic of childhood and adult obesity and linked to an unhealthy metabolic 
phenotype.
Large for gestational age (LGA) is defined as a birth weight above the 90th percentile for the corresponding ges-
tational age (GA)1. The maternal factors most closely associated with LGA are maternal obesity, excessive gesta-
tional weight gain, maternal gestational diabetes mellitus (GDM), pregestational obesity, and maternal stress2–9. 
Fetal factors associated with LGA consist primarily of genetic or chromosomal disorders. LGA prevalence is 
estimated at between 4.6% and 15.3%10 and is influenced by ethnicity, with higher rates found in children born to 
African American and non-Hispanic Asian American women in U.S. studies11,12.
Excessive fetal growth has negative consequences that extend beyond the neonatal period and these include 
medium- and long-term neurological, behavioral, and cardiovascular impacts13–16. LGA newborns are also at an 
increased risk of obesity17–20, metabolic syndrome21,22, and insulin resistance23 in later life. They have also been 
found to have elevated leptin and fasting insulin and homeostasis model assessment (HOMA) index levels24 
during childhood, in addition to elevated adiponectin levels25, despite previous reports to the contrary from 
other studies of insulin states. The risk of obesity in LGA newborns increases with co-occurrence of maternal 
overweight/obesity or diabetes mellitus26.
Dysregulation of fatty acid oxidation and subsequent lipotoxicity play an important role in the pathophysi-
ology of obesity-induced insulin resistance27,28. Analysis of acylcarnitine profiles by tandem mass spectrometry 
(MS/MS) in dried-blood spots has been used to investigate fatty acid oxidation alterations in obesity and type 1 
and type 2 diabetes mellitus in both human and animal models29–32. A recent systematic review, however, failed to 
identify a consistent metabolite profile in GDM33.
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The aim of this study was to characterize postnatal plasma acylcarnitine profiles in a cohort of LGA newborns. 
As a secondary outcome, we analyzed and compared the acylcarnitine fingerprint of LGA infants born to mothers 
with and without gestational diabetes (LGA-GDM and LGA-noGDM respectively).
Results
General characteristics of the study population. In total, 2514 newborns (1362 males and 1152 
females) were included over the 1-year study period. None of them met the exclusion criteria. There were 2302 
full-term newborns and 212 preterm newborns, with a medium GA of 39 weeks and the following anthropomet-
ric characteristics: mean birth weight, 3225 ± 591 g; mean birth length, 49.05 ± 2.47 cm; and mean head circun-
ference, 34.3 ± 1.66 cm. In the preterm group, the respective measurements were 2127 ± 644 g, 44.03 ± 3.88 cm, 
and 31.13 ± 2.42 cm. The distribution according to birth weight percentile was 9% for small for GA (SGA) new-
borns (250/2514), 80.2% for appropriate for GA (AGA) newborns (2018/2514), and 9.7% for LGA newborns 
(246/2514). All birth measurements were higher in LGA newborns: weight, 4118 ± 234 g; length, 51.95 ± 1.36 cm; 
and head circumference, 35.97 ± 1.36 cm. Only one preterm newborn included in the study was classified as LGA. 
A flow diagram of the cohort is shown in Supplementary Figure 1.
The percentage of newborns in the severe LGA group (>97th percentile) was 3% (75/2514), which is identical 
to the percentage of newborns in the severe SGA group (<3rd percentile).There were thus 2364 newborns in the 
AGA(3-97) group, which contained newborns with a birth weight ≥3rd percentile and ≤97th percentile.
Nine percent (246/2514) of the newborns were born to mothers with a history of GDM; 81.4% of the moth-
ers received dietary treatment and 18.6% required insulin treatment. The breakdown of the LGA group was as 
follows: 42 LGA-GDM newborns and 204 LGA-noGDM newborns. No significant differences were observed 
between the mothers in these subgroups for either age or obstetric comorbidities (Supplementary Table 1).
Acylcarnitine profiles. All acylcarnitine values are expressed as medians and the corresponding 95% con-
fidence interval is given in the tables. Compared with AGA newborns, LGA newborns had higher levels of FC, 
TC, tAC (p < 0.01), tACm, tACl, and, in particular, tACs (p < 0.01). As shown in Table 1, LGA newborns had 
the highest tAC/FC ratio (0.795) and the lowest FC/TC ratio (0.557). This was close to the cutoff for neonatal 
carnitine insufficiency (tAC/FC > 0.83) and carnitine deficiency (FC/TC < 0.54), suggesting reduced carnitine 
storage in this group (SGA, 0.603; AGA, 0.578; and LGA, 0.557) (p < 0.001). Separate analysis of the various 
acylcarnitines showed remarkably higher levels of C2 and C3 in LGA newborns (p < 0.01), although plasma 
concentrations for the majority of short- and long-chain acylcarnitines were also higher in the LGA group. The 
C8/C2 ratio was considerably lower in the LGA group (0.0078 vs. 0.0097 for the AGA group, p < 0.01). The most 
significant differences between LGA and AGA newborns are summarized in Fig. 1.
Although severe LGA newborns had higher levels of FC, TC, tAC, tACs, tACm, and tACl, the only signifi-
cant difference compared with AGA(3-97) newborns were higher levels of C3 (p < 0.05) (Table 2). In addition, no 
increase in carnitine deficiency or insufficiency markers was observed in this group.
The comparison between LGA-GDM and LGA-noGDM newborns revealed that a history of gestational dia-
betes was associated with higher levels of FC, TC, and short-chain acylcarnitines, including propionylcarnitine 
(LGA-GDM: 3.33 µmol/L; LGA-noGDM: 2.69 µmol/L), and lower levels of medium- and long-chain acylcarni-
tines, although the differences were not significant (Table 3). Analysis of the individual acylcarnitines revealed no 
remarkable differences between the two subgroups.
Discussion
Disturbances in fetal nutrition, such as intrauterine growth restriction (IUGR) and macrosomia, can impact 
health during adolescence and adulthood13–16,34 and are risk factors for later overweight17–20,35,36. Animal studies 
have shown that fetal overnutrition results in increased adiposity in newborns, leading to insulin resistance sim-
ilar to that seen in cases of postnatal overnutrition37. Given the high worldwide prevalence of child obesity and 
overweight38, improved knowledge of metabolic homeostasis in higher-risk subgroups, such as LGA newborns, 
is essential for identifying possible treatment targets.
Recent investigations have identified abnormalities in the metabolic profiles of obese adults and children, 
such as increased plasma concentrations of branched-chain amino acids (BCAAs) (valine, leucine, and isoleu-
cine), BCAA metabolism byproducts (e.g. alanine, glutamate/glutamine), C3 and C5 acylcarnitines, and aromatic 
amino acids (phenylalanine and tyrosine)29,39–44. The increase in BCAA and short-chain acylcarnitine concen-
trations is linked to elevated protein intake45, and levels are positively correlated with adiposity46,47 and strongly 
associated with IR29,32,44,48. The metabolic environment in LGA is less well-known. Higher levels of adipokines49, 
BCAAs, and other metabolites, such as alanine, glutamine, threonine, citric acid, glycerol, and glucose, have been 
detected in cord-blood samples of LGA newborns50, and similar findings have been reported for myo-inositol 
levels in urine samples51.
Ours is the first study to characterize acylcarnitine profiles in LGA newborns. In line with the results of obesity 
studies in children41,43 and adults29,31, our data show that LGA newborns have increased postnatal levels of C3, a 
product of mitochondrial BCAA catabolism, and in particular of isoleucine and valine catabolism29. BCAAs act 
as signaling molecules of nutritional status52. Increased concentrations in obese and insulin-resistant humans 
may be caused by down-regulation of BCAA oxidation enzymes in adipose tissue53,54, as has been observed in ani-
mal models with genetic or diet-induced obesity55. Propionylcarnitine is a carnitine conjugate of propionyl-CoA, 
which has been identified as a potential substrate for odd-chain fatty acid synthesis56. Moreover, C3 and C5 lev-
els are promising biomarkers for discriminating metabolic wellness in obese individuals57, as higher levels have 
been observed in metabolically unhealthy individuals, independently of body mass index58. Consistent with these 
observations, the LGA newborns in our study had higher C3 (p < 0.001) and C5 levels than AGA newborns, and 
the concentrations of C3 were even higher than those observed in obese children41,43 and adults29. This could 
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reflect an unhealthy metabolic status in LGA newborns with potential complications in later life. The LGA group 
also had higher C2 plasma levels, and these were particularly evident in severe LGA newborns. C2 may play a role 
in insulin resistance through its interaction with acetyl-CoA via carnitine acetyl-CoA transferase. This enzyme 
seems to act as a positive regulator of total body glucose tolerance and muscle activity of pyruvate dehydroge-
nase59. C2 levels are increased in prediabetic states60, diabetes mellitus30,32,60, and metabolic syndrome32, and are 
significantly and positively correlated with HbA1c levels30. Interestingly, the levels in the LGA group were higher 
than those reported for diabetic adult patients30,32,60.
One of the most notable differences between LGA and AGA newborns in our study was the significantly 
higher tACs levels in the LGA group (p < 0.0001). This observation is consistent with reports of increased tACs in 
obesity, impaired glucose tolerance, and diabetes mellitus61.
The acylcarnitine pattern of increased tAC, tACs, C2, and C3 levels was more evident in the SGA group, sup-
porting previous observations in animal models62 and neonatal studies63, and suggesting an impaired fatty acid 
metabolism in both fetal growth disorders.
In agreement with the profile described for overweight adults29 and children64, LGA newborns also showed 
higher (though not significantly so) concentrations of medium- and long-chain acylcarnitines than AGA 
newborns.
A strong correlation was recently demonstrated between carnitine and body composition65. Although we 
observed slightly higher plasma concentrations of free carnitine in LGA newborns, our data also showed a 
greater tendency towards carnitine deficiency (p < 0.05) and insufficiency (p < 0.001) in this group. Increases 
in tAC/FC ratio precede a decrease in total plasma carnitine and indicate low tissue bioavailability of FC66. The 
higher FC levels in LGA contrast with the carnitine depletion reported for diet-induced obesity67. Nevertheless, 
SGA (n: 250) AGA (n:2018) LGA (n:246) SGA vs AGA AGA vs LGA
Median Range Median Range Median Range P1 95% CI P2 95%CI
FC 33.58 8.27–80.24 27.96 7.12–100.56 28.20 9.23–80.16 6.8e−8 3.73, 6.72 NS −0.90, 1.75
TC 57.57 17.00–118.44 49.01 20.05–135.89 51.20 23.26–114.70 2.09e−7 5.68, 10.36 NS 0.34, 4.47



































































































































































































































































































































































































































tAC/FC 0.657 0.31–1.651 0.728 0.246–2.42 0.795 0.332–1.634 0.005 –0.101, −0.03 0.036 0.019, 0.094
FC/TC 0.603 0.37–0.761 0.578 0.292–0.803 0.557 0.38–0.751 0.014 0.011, 0.033 0.0001 −0.031, −0.009
Table 1. Acylcarnitine profiles (µmol/L) according to birth weight based on the 10th and 90th percentiles. p1, 
comparison between SGA and AGA newborns; p2, comparison between AGA and LGA newborns; 95% CI, 
95% confidence interval; FC, free carnitine; TC, total carnitine; tAC, total acylcarnitines; tACs, total short-chain 
acylcarnitines; tACm, total medium-chain acylcarnitines; tACl, total long-chain acylcarnitines; SGA, small for 
gestational age; AGA, appropriate for gestational age; LGA, large for gestational age; NS, p not significant.
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metabolomic studies of obesity have also shown higher levels of carnitine in obese children43. Carnitine insuffi-
ciency in our cohort appears to be unrelated to antenatal exposure to GDM. This is relevant given the proposed 
causative role of carnitine insufficiency in mitochondrial dysfunction and obesity-related impairments in glucose 
tolerance68. It is also consistent with reports that document that GDM in pregnant women does not negatively 
affect the efficiency of the carnitine system69. We did not find any postnatal differences between acylcarnitine 
profiles in LGA-GDM and LGA-noGDM newborns in our study, although the former had higher concentrations 
of FC, TC, tAC and tACs. In line with this observation, higher FC and TC levels have been reported in pregnant 
women with GDM versus healthy pregnant women at 30–33 weeks of gestation69. We do not consider that the 
absence of significant differences between the LGA-GMD and LGA-no GDM groups is due to sample size, as the 
minimum detectable effect sizes for the samples used in each comparison (with 5% significance and 80% statis-
tical power) were 0.2 for AGA vs LGA and AGA vs SGA (Table 1), 0.25 for SGA vs LGA (Table 1), 0.33 for AGA 
vs LGA (Table 2), and 0.48 for LGA-noGMD vs LGA-GMD (Table 3). This means that, even in the worst-case 
scenario (Table 3), we are able to detect true between-group differences of higher than 50% of the SD, which are 
considered medium effect sizes70.
Our findings describe a postnatal acylcarnitine profile in LGA newborns that is characteristic of obesity 
and associated with the development of insulin resistance and prediabetic states, supporting the view that early 
imbalance in metabolic homeostasis in LGA newborns could contribute to deleterious effects in the long term. 
Identification of this profile, linked to an unhealthy metabolic phenotype, in the postnatal period could help to 
establish early dietary intervention and follow-up to reduce the risk of overweight and metabolic syndrome in 
later life.
Patients and Methods
Study design. The acylcarnitine profiles of LGA newborns were determined in a 1-year observational study 
approved by the Research Ethics Committee of Galicia, Spain (registry number 2015/315). The processing of clin-
ical data for research purposes at the beginning of the study and the study protocol complied with the principles 
of the Helsinki Declaration of 1964, as revised in October 2013 in Fortaleza, Brazil.
Figure 1. Main differences between large for gestational age (LGA) and appropriate for gestational age (AGA) 
newborns.
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Patients. This study was conducted at Hospital Clínico Universitario de Santiago de Compostela, a tertiary 
hospital in north-west Spain. All newborns born in or referred to our hospital during the first 48 hours of life 
over the period of 1 year (2015) were included in the study. Informed consent was obtained from parents or 
legal guardians. Infants with an established diagnosis of an inborn error of metabolism known to alter acylcarni-
tine profiles (primary systemic carnitine deficiency, mitochondrial fatty acid ß-oxidation defects, ß-ketothiolase 
deficiency, propionic, methylmalonic or isovaleric acidemia, 3-methylcrotonyl-CoA carboxylase deficiency, 
3-hydroxy-3-methylglutaryl-CoA lyase deficiency, or 3-methylglutaconic aciduria) were excluded from the anal-
ysis. The following variables were recorded at birth: sex, gestational age, weight (g), length (cm), head circumfer-
ence (cm), history of GDM, and treatments received (dietary and/or insulin treatment).
Newborns were classified into the following groups according to their birth weight: AGA (≥10th percentile 
and ≤90th percentile of birth weight for GA), SGA (<10th percentile of birth weight for GA), and LGA (>90th 
percentile of birth weight for GA). For additional analyses we also classified newborns with a birth weight greater 
than the 97th percentile for GA into a severe LGA group.
Birth weight percentiles and z-scores for GA were calculated using the online nutritional assessment tool of 
the Spanish Society of Gastroenterology, Hepatology and Nutrition (www.gastroinf.es), which is based on Spanish 
neonatal growth curves71.
GDM was defined according to the criteria established in the 2016 Guidelines of the American Diabetes 
Association72 using the two-step diagnostic strategy: 1) if plasma glucose is ≥140 mg/dL (7.8 mmol/L) in the 
1-hour glucose loading-test, pregnant women must 2) undergo a glucose tolerance test (administration of 100 g 
of glucose after 8 hours of fasting with subsequent sequential blood sampling). Diagnosis is confirmed when two 
or more of the following glucose criteria are fulfilled: fasting, ≥105 mg/dL (5.8 mmol/L); 1 hour, ≥190 mg/dL 
(10.6 mmol/L); 2 hours, ≥165 mg/dL (9.2 mmol/L); and 3 hours, ≥145 mg/dL (8.0 mmol/L).
SGA (n:75) AGA(3–97) (n:2364) LGA (n:75) SGA VS AGA AGA VS LGA
Median Range Median Range Median Range P1 95%CI P2 95% CI
FC 35.43 14.22–64.09 28.31 7.12–100.56 28.22 11.58–73.43 0.009 4.01,9.29 NS −2.29, 2.685
TC 62.31 25.14–105.97 50.12 17.00–135.89 52.33 25.14–114.70 1.72e−6 8.046, 16.168 NS −2.361, 5.609




































































































































































































































































































































































































































tAC/FC 0.693 0.314–1.58 0.724 0.246–2.42 0.776 0.431–1.634 NS −0.096, 0.042 NS −0.014, 0.112
FC/TC 0.591 0.388–0.761 0.580 0.292–0.803 0.563 0.38–0.699 NS −0.008, 0.032 NS −0.038, 0.001
Table 2. Acylcarnitine profiles (µmol/L) according to birth weight based on 3rd and 97th percentiles. p1, 
comparison between severe SGA and AGA(3–97) groups; p2, comparison between AGA(3–97) and severe LGA 
groups; 95% CI, 95% confidence interval; FC, free carnitine; TC, total carnitine; tAC, total acylcarnitines; 
tACs, total short-chain acylcarnitines; tACm, total medium-chain acylcarnitines; tACl, total long-chain 
acylcarnitines; SGA, small for gestational age; AGA, appropriate for gestational age; LGA, large for gestational 
age; NS, p not significant.
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Based on the corresponding obstetric history of gestational diabetes, LGA newborns were sub-classified as 
LGA-GDM (co-occurrence of gestational diabetes) or LGA-noGDM (absence of GDM).
Tandem mass spectrometry and study parameters. Analyses of free carnitine and acylcarnitines 
were performed on a tandem mass spectrometer coupled to a triple quadrupole analyzer (ESI-MS/MS API 2000; 
Applied Biosystems Sciex, Toronto, Canada) following an established methodology73.
The plates were prepared using the following protocol. The paper blood sample disks and patterns were 
cut using a BSD 700 automatic drill (BSD tech., Brisbane, Australia) and hand drills followed by microplate 
placement and addition to each well of methanol. Acylcarnitines were purified with methanol and stable 
isotope-labeled patterns were used to determine their respective concentrations. The acylcarnitines were then 
extracted by vortex shaking for 25 minutes. Subsequently, all the methanol was transferred to another plate to 
distil the blood disks and then evaporated in a gas extractor. The acylcarnitines were derivatized with butanol 
to their butyl-esters in an acid medium to increase the selectivity of the technique. This was done with the 
addition of 3N HCl in n-butanol followed by heating at 65 ± 5 °C for 20 minutes and cooling for 5 minutes in a 
freezer. Excess butanol was evaporated to dryness and once the evaporated plates were at room temperature, a 
new solution was prepared with 100 μL of the mobile phase of the chromatograph (acetonitrile: water, 1:1). The 
plates were then covered with foil, vortexed for 5 minutes, and finally analyzed (precursor m/z 120–280 amu).
The reagents were prepared using water purified with a Milli-Q system (Millipore) and the mobile phase was 
composed of acetonitrile (LiCrosolv Merck, ref. 00030) and formic acid 0.005% (Merck, ref.02264).
A comprehensive analysis of acylcarnitine profiles was conducted by MS/MS using dried-blood spots 
collected on the third day of life for expanded newborn screening. We analyzed: short-chain acylcarnitines: 
acetyl- (C2), propionyl- (C3), propenyl- (C3:1), C4-, 3-OH-butyryl- (C4-OH), C5- and tiglyl-carnitine (C5:1); 
medium-chain acylcarnitines: C6-, 3-hydroxy-hexanoyl- (C6-OH), C8-, octenoyl- (C8:1), methylmalonyl- 
(C4DC), C10-, decenoyl- (C10:1), decadienoyl- (C10:2), C12- and dodecenoyl-carnitine (C12:1); and 
long-chain acylcarnitines: C14-, myristoleyl- (C14:1), hydroxymyristoyl- (C14-OH), C16-, hexadecenoyl- 
(C16:1), 3-hydroxi-hexadecanoyl- (C16-OH), 3-hydroxypalmitoleylc- (C16:1-OH), C18-, oleyl- (C18:1), 
linoleyl- (C18:2), hydroxyoleyl- (C18:1-OH) and 3-hydroxy-linoleyl-carnitine (C18:2-OH). It should be noted 
that the analytical method employed does not allow for the differentiation of isobaric acylcarnitines. The 
following parameters were also assessed: total short-chain acylcarnitines (tACs), total medium-chain acyl-
carnitines (tACm), total long-chain (tACl) acylcarnitines (the sum of short-, medium-, and long-chain acyl-
carnitines, respectively), total acylcarnitines (tAC) (the sum of all acylcarnitines studied); total carnitine (TC), 
defined as the sum of free carnitine (FC) and total acylcarnitines (tAC), FC/TC ratio (values <0.54 in neonates 
are suggestive of carnitine deficiency), and tAC/FC ratio (values >0.83 in newborns are indicative of carnitine 
insufficiency)74. We also evaluated three acylcarnitine ratios typically included in neonatal screening: C8/C2, 
C8/C10, and FC/C16.
Statistical analyses. Data were analyzed using the R statistical package (version 3.2.1; R Project for 
Statistical Computing). Sample normality was assessed using the Kolmogorov-Smirnov test. ANOVA was used to 
compare normally distributed data, and the Kruskal–Wallis test was used to compare non-normally distributed 
data. Qualitative variables were compared using Fisher’s exact test. Normal samples with unknown variance were 
compared using Student’s t-test, while non-normally distributed data were compared using the Wilcoxon rank 
test. Finally, the p-values obtained were adjusted using Bonferroni correction. Only adjusted p-values < 0.05 were 
considered statistically significant.
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